Silver Book Fact

According to the Pharmaceutical Research and Manufacturers of America, a medicine in development targets CA125, a surface protein, or antigen, that is released in excess quantities by some ovarian cancers. The medicine, a monoclonal antibody, would stimulate the immune system to attack the protein–killing the tumors.

Alzheimer's Association. Saving Lives, Saving Money: Dividends for Americans investing in Alzheimer research. Falls Church, VA: The Lewin Group; 2004

Reference

Title
Saving Lives, Saving Money: Dividends for Americans investing in Alzheimer research
Publisher
The Lewin Group
Publication Date
2004
Authors
Alzheimer's Association

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • According to the Pharmaceutical Research and Manufacturers of America, a medicine in development that is a monoclonal antibody, targets the epidermal growth factor receptor. Because cancer cells can become…  
  • Death rates from breast cancer have steadily decreased in women since 1990. This decrease represents progress in both early detection and improved treatment.  
  • A one percent reduction in lung, colorectal, breast, leukemia, pancreatic, and brain cancer mortality would reduce productivity costs by $814 million per year.  
  • According to the Pharmaceutical Research and Manufacturers of America, a medicine in development targets late-stage metastatic melanoma. The medicine contains a gene encoding antigen that may be able to…  
  • The 5-year survival rate for cancer has gone up 40 percent in the last 40 years.